Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Mather Group LLC.

Mather Group LLC. increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 236.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,937 shares of the medical equipment provider’s stock after acquiring an additional 2,063 shares during the quarter. Mather Group LLC.’s holdings in Hologic were worth $212,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Prentiss Smith & Co. Inc. grew its stake in Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after acquiring an additional 130 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares in the last quarter. First Horizon Advisors Inc. grew its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Brooklyn Investment Group increased its stake in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares in the last quarter. Finally, Empirical Finance LLC raised its position in shares of Hologic by 1.8% during the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.88% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $65.45 on Friday. The company has a market cap of $14.77 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 2.35 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $72.63 and a two-hundred day moving average price of $77.86. Hologic, Inc. has a 12-month low of $64.87 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of analyst reports. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. lifted their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday. Finally, Morgan Stanley decreased their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Nine investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.